A combined bottom-up/top-down approach to prepare a sterile injectable nanosuspension

被引:28
作者
Hu, Xi [1 ]
Chen, Xi [1 ]
Zhang, Ling [1 ]
Lin, Xia [2 ]
Zhang, Yu [1 ]
Tang, Xing [1 ]
Wang, Yanjiao [1 ]
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmaceut, Shenyang, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200030, Peoples R China
关键词
Nanosuspension; Physical modification; Controlled crystallization; Wettability; High-pressure homogenization; HIGH-PRESSURE HOMOGENIZATION; DRUG NANOCRYSTALS; NANOPARTICLES; FORMULATION; STABILITY; DELIVERY;
D O I
10.1016/j.ijpharm.2014.06.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To prepare a uniform nanosuspension of strongly hydrophobic riboflavin laurate (RFL) allowing sterile filtration, physical modification (bottom-up) was combined with high-pressure homogenization (top-down) method. Unlike other bottom-up approaches, physical modification with surfactants (TPGS and PL-100) by lyophilization controlled crystallization and compensated for the poor wettability of RFL. On one hand, crystal growth and aggregation during freezing was restricted by a stabilizer-layer adsorbed on the drug surface by hydrophobic interaction. On the other hand, subsequent crystallization of drug in the sublimation process was limited to the interstitial spaces between solvent crystals. After lyophilization, modified drug with a smaller particle size and better wettability was obtained. When adding surfactant solution, water molecules passed between the hydrophilic groups of surface active Molecules and activated the polymer chains allowing them to stretch into water. The coarse suspension was crushed into a nanosuspension (MP=162 nm) by high-pressure homogenization. For long term stability, lyophilization was applied again to solidify the nanosuspension (sorbitol as cryoprotectant). A slight crystal growth to about 600 nm was obtained to allow slow release for a sustained effect after muscular administration. Moreover, no paw-licking responses and very slight muscular inflammation demonstrated the excellent biocompatibility of this long-acting RFL injection. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:130 / 139
页数:10
相关论文
共 23 条
[1]   DYNAMICAL THEORY OF X-RAY DIFFRACTION IN CRYSTALS WITH DEFECTS [J].
AFANASEV, AM ;
KOHN, VG .
ACTA CRYSTALLOGRAPHICA SECTION A-CRYSTAL PHYSICS DIFFRACTION THEORETICAL AND GENERAL CRYSTALLOGRAPHY, 1971, A 27 (SEP1) :421-&
[2]   Structural relationships, thermal properties, and physicochemical characterization of anhydrous and solvated crystalline forms of tetroxoprim [J].
Caira, MR ;
Bettinetti, G ;
Sorrenti, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (02) :467-481
[3]   AN ANIMAL-MODEL FOR ASSESSING PAIN-ON-INJECTION OF ANTIBIOTICS [J].
CELOZZI, E ;
LOTTI, VJ ;
STAPLEY, EO ;
MILLER, AK .
JOURNAL OF PHARMACOLOGICAL METHODS, 1980, 4 (04) :285-289
[4]   An overview of liposome lyophilization and its future potential [J].
Chen, Chengjun ;
Han, Dandan ;
Cai, Cuifang ;
Tang, Xing .
JOURNAL OF CONTROLLED RELEASE, 2010, 142 (03) :299-311
[5]   Controlling drug nanoparticle formation by rapid precipitation [J].
D'Addio, Suzanne M. ;
Prud'homme, Robert K. .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (06) :417-426
[6]   A novel bottom-up process to produce drug nanocrystals: Controlled crystallization during freeze-drying [J].
de Waard, H. ;
Hinrichs, W. L. J. ;
Frijlink, H. W. .
JOURNAL OF CONTROLLED RELEASE, 2008, 128 (02) :179-183
[7]  
Francois MKJ, 2003, patent United States patent, Patent No. [6555544 B2, 6555544]
[8]   Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery [J].
Ganta, Srinivas ;
Paxton, James W. ;
Baguley, Bruce C. ;
Garg, Sanjay .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 367 (1-2) :179-186
[9]  
Hu X, 2013, DRUG DELIV
[10]   Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation [J].
Keck, CM ;
Müller, RH .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 62 (01) :3-16